{"id":6690,"date":"2025-10-17T13:14:16","date_gmt":"2025-10-17T11:14:16","guid":{"rendered":"https:\/\/www.ffrdiabete.org\/?p=6690"},"modified":"2025-10-17T13:36:55","modified_gmt":"2025-10-17T11:36:55","slug":"a-promising-avenue-for-the-treatment-of-mash","status":"publish","type":"post","link":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/","title":{"rendered":"T2D, kidney protection, peripheral arterial disease &amp; SGLT2 inhibitors: act early"},"content":{"rendered":"<p><span style=\"color: #143877; font-family: Calibri, sans-serif; font-size: large;\"><strong>Nephroprotective<\/strong> measures in patients with <strong>type 2 diabetes<\/strong> were reviewed by Prof. Ariane SULTAN during the annual meeting of the Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD), held in Paris from April 1 to 4, 2025.<\/span><\/p>\n<p><span style=\"color: #143877; font-family: Calibri, sans-serif; font-size: large;\">The assessment of <strong>kidney function<\/strong> remains insufficiently performed in <strong>patients with type 2 diabetes<\/strong>, according to <strong>Study ENTRED 3<\/strong>. <\/span><\/p>\n<p><span style=\"color: #143877; font-family: Calibri, sans-serif; font-size: large;\"><strong>SGLT2 inhibitors<\/strong> (sodium-glucose cotransporter-2 inhibitors \u2014 also known as gliflozins) are now considered first-line agents for <strong>kidney protection<\/strong>. They help prevent the risk of acute and\/or chronic kidney failure and slow its progression toward end-stage renal disease, thanks to their proven efficacy supported by numerous expert reviews and clinical guidelines.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.diabetologie-pratique.com\/axistv\/video\/dt2-nephroprotection-atteinte-arterielle-peripherique-isglt2-agir-precocement\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-6693\" src=\"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2025\/10\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23-1024x574.jpg\" alt=\"\" width=\"624\" height=\"350\" srcset=\"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2025\/10\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23-1024x574.jpg 1024w, https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2025\/10\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23-300x168.jpg 300w, https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2025\/10\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23-768x431.jpg 768w, https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2025\/10\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23-1536x861.jpg 1536w, https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2025\/10\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23.jpg 1616w\" sizes=\"auto, (max-width: 624px) 100vw, 624px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Prof. Bruno VERG\u00c8S<\/strong>, President of the FFRD, discussed fluid and electrolyte disorders in patients with type 2 diabetes (T2D) who suffer from impaired kidney function:<\/p>\n<ul>\n<li>Hyponatremia: a decrease in blood <strong>sodium<\/strong> levels (natremia) below 135mmol\/L,<\/li>\n<li>Hypomagnesemia: an abnormally low blood <strong>magnesium<\/strong> level (plasma concentration) below<br \/>0.65mmol\/L,<\/li>\n<li>Hyperkalemia: an elevated <strong>potassium<\/strong> level in the blood.<\/li>\n<\/ul>\n<p><strong>Prof. Olivier BOURRON<\/strong>, recipient of an FFRD grant in 2023, reminded that T2D patients with peripheral arterial disease and neuropathy remain at <strong>high cardiovascular and renal risk<\/strong>, and at very high risk of <strong>foot complications<\/strong>.<\/p>\n<p>Early intervention is essential. SGLT2 inhibitors play a key role in therapeutic strategies, provided that careful podiatric monitoring is maintained. <\/p>\n<p><em>Video from Len axis in Diab\u00e9tologie Pratique.<\/em><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.diabetologie-pratique.com\/axistv\/video\/dt2-nephroprotection-atteinte-arterielle-peripherique-isglt2-agir-precocement\" target=\"_blank\" rel=\"noopener\"><strong>DISCOVER THIS VIDEO!<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nephroprotective measures in patients with type 2 diabetes were reviewed by Prof. Ariane SULTAN during the annual meeting of the Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD), held in Paris from April 1 to 4, 2025. The assessment of kidney function remains insufficiently performed in patients with type 2 diabetes, according to Study ENTRED 3. SGLT2 inhibitors&hellip;<\/p>\n","protected":false},"author":2,"featured_media":6705,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6690","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-non-classifiee","category-1","description-off"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>T2D, kidney protection, peripheral arterial disease &amp; SGLT2 inhibitors: act early - Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"T2D, kidney protection, peripheral arterial disease &amp; SGLT2 inhibitors: act early - Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD\" \/>\n<meta property=\"og:description\" content=\"Nephroprotective measures in patients with type 2 diabetes were reviewed by Prof. Ariane SULTAN during the annual meeting of the Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD), held in Paris from April 1 to 4, 2025. The assessment of kidney function remains insufficiently performed in patients with type 2 diabetes, according to Study ENTRED 3. SGLT2 inhibitors&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-17T11:14:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-17T11:36:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2025\/10\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23_Vignette.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1480\" \/>\n\t<meta property=\"og:image:height\" content=\"894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"St\u00e9phanie NOUGARET\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@FondationFFRD\" \/>\n<meta name=\"twitter:site\" content=\"@FondationFFRD\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"St\u00e9phanie NOUGARET\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/a-promising-avenue-for-the-treatment-of-mash\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/a-promising-avenue-for-the-treatment-of-mash\\\/\"},\"author\":{\"name\":\"St\u00e9phanie NOUGARET\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#\\\/schema\\\/person\\\/011078a0c444e305b94c3b4630b66d8c\"},\"headline\":\"T2D, kidney protection, peripheral arterial disease &amp; SGLT2 inhibitors: act early\",\"datePublished\":\"2025-10-17T11:14:16+00:00\",\"dateModified\":\"2025-10-17T11:36:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/a-promising-avenue-for-the-treatment-of-mash\\\/\"},\"wordCount\":236,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/a-promising-avenue-for-the-treatment-of-mash\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ffrdiabete.org\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23_Vignette.jpg\",\"articleSection\":[\"Non classifi\u00e9(e)\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/a-promising-avenue-for-the-treatment-of-mash\\\/\",\"url\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/a-promising-avenue-for-the-treatment-of-mash\\\/\",\"name\":\"T2D, kidney protection, peripheral arterial disease &amp; SGLT2 inhibitors: act early - Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/a-promising-avenue-for-the-treatment-of-mash\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/a-promising-avenue-for-the-treatment-of-mash\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.ffrdiabete.org\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23_Vignette.jpg\",\"datePublished\":\"2025-10-17T11:14:16+00:00\",\"dateModified\":\"2025-10-17T11:36:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/a-promising-avenue-for-the-treatment-of-mash\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/a-promising-avenue-for-the-treatment-of-mash\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/a-promising-avenue-for-the-treatment-of-mash\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.ffrdiabete.org\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23_Vignette.jpg\",\"contentUrl\":\"https:\\\/\\\/www.ffrdiabete.org\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23_Vignette.jpg\",\"width\":1480,\"height\":894,\"caption\":\"Screenshot\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/a-promising-avenue-for-the-treatment-of-mash\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"T2D, kidney protection, peripheral arterial disease &amp; SGLT2 inhibitors: act early\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/\",\"name\":\"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD\",\"description\":\"Pour que la recherche sur le diab\u00e8te avance\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#organization\"},\"alternateName\":\"FFRD\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#organization\",\"name\":\"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD\",\"alternateName\":\"FFRD\",\"url\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ffrdiabete.org\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/FFRD-logo-main-retrina.png\",\"contentUrl\":\"https:\\\/\\\/www.ffrdiabete.org\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/FFRD-logo-main-retrina.png\",\"width\":462,\"height\":211,\"caption\":\"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/FondationFFRD\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/fondation-francophone-pour-la-recherche-sur-le-diabte---ffrd\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ffrdiabete.org\\\/en\\\/#\\\/schema\\\/person\\\/011078a0c444e305b94c3b4630b66d8c\",\"name\":\"St\u00e9phanie NOUGARET\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/465019f2f3ec45dde981031deb150e5820e952f2838cd6adafd57dcaa95e8c4c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/465019f2f3ec45dde981031deb150e5820e952f2838cd6adafd57dcaa95e8c4c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/465019f2f3ec45dde981031deb150e5820e952f2838cd6adafd57dcaa95e8c4c?s=96&d=mm&r=g\",\"caption\":\"St\u00e9phanie NOUGARET\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"T2D, kidney protection, peripheral arterial disease &amp; SGLT2 inhibitors: act early - Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/","og_locale":"en_US","og_type":"article","og_title":"T2D, kidney protection, peripheral arterial disease &amp; SGLT2 inhibitors: act early - Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD","og_description":"Nephroprotective measures in patients with type 2 diabetes were reviewed by Prof. Ariane SULTAN during the annual meeting of the Soci\u00e9t\u00e9 Francophone du Diab\u00e8te (SFD), held in Paris from April 1 to 4, 2025. The assessment of kidney function remains insufficiently performed in patients with type 2 diabetes, according to Study ENTRED 3. SGLT2 inhibitors&hellip;","og_url":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/","og_site_name":"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD","article_published_time":"2025-10-17T11:14:16+00:00","article_modified_time":"2025-10-17T11:36:55+00:00","og_image":[{"width":1480,"height":894,"url":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2025\/10\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23_Vignette.jpg","type":"image\/jpeg"}],"author":"St\u00e9phanie NOUGARET","twitter_card":"summary_large_image","twitter_creator":"@FondationFFRD","twitter_site":"@FondationFFRD","twitter_misc":{"Written by":"St\u00e9phanie NOUGARET","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/#article","isPartOf":{"@id":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/"},"author":{"name":"St\u00e9phanie NOUGARET","@id":"https:\/\/www.ffrdiabete.org\/en\/#\/schema\/person\/011078a0c444e305b94c3b4630b66d8c"},"headline":"T2D, kidney protection, peripheral arterial disease &amp; SGLT2 inhibitors: act early","datePublished":"2025-10-17T11:14:16+00:00","dateModified":"2025-10-17T11:36:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/"},"wordCount":236,"publisher":{"@id":"https:\/\/www.ffrdiabete.org\/en\/#organization"},"image":{"@id":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2025\/10\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23_Vignette.jpg","articleSection":["Non classifi\u00e9(e)"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/","url":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/","name":"T2D, kidney protection, peripheral arterial disease &amp; SGLT2 inhibitors: act early - Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD","isPartOf":{"@id":"https:\/\/www.ffrdiabete.org\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/#primaryimage"},"image":{"@id":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2025\/10\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23_Vignette.jpg","datePublished":"2025-10-17T11:14:16+00:00","dateModified":"2025-10-17T11:36:55+00:00","breadcrumb":{"@id":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/#primaryimage","url":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2025\/10\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23_Vignette.jpg","contentUrl":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2025\/10\/DiabetoPratique_SFD_Nephroprotection-DT2_2025-04-23_Vignette.jpg","width":1480,"height":894,"caption":"Screenshot"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ffrdiabete.org\/en\/"},{"@type":"ListItem","position":2,"name":"T2D, kidney protection, peripheral arterial disease &amp; SGLT2 inhibitors: act early"}]},{"@type":"WebSite","@id":"https:\/\/www.ffrdiabete.org\/en\/#website","url":"https:\/\/www.ffrdiabete.org\/en\/","name":"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD","description":"Pour que la recherche sur le diab\u00e8te avance","publisher":{"@id":"https:\/\/www.ffrdiabete.org\/en\/#organization"},"alternateName":"FFRD","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ffrdiabete.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ffrdiabete.org\/en\/#organization","name":"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD","alternateName":"FFRD","url":"https:\/\/www.ffrdiabete.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ffrdiabete.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2023\/08\/FFRD-logo-main-retrina.png","contentUrl":"https:\/\/www.ffrdiabete.org\/wp-content\/uploads\/2023\/08\/FFRD-logo-main-retrina.png","width":462,"height":211,"caption":"Fondation Francophone pour la Recherche sur le Diab\u00e8te - FFRD"},"image":{"@id":"https:\/\/www.ffrdiabete.org\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/FondationFFRD","https:\/\/www.linkedin.com\/company\/fondation-francophone-pour-la-recherche-sur-le-diabte---ffrd\/"]},{"@type":"Person","@id":"https:\/\/www.ffrdiabete.org\/en\/#\/schema\/person\/011078a0c444e305b94c3b4630b66d8c","name":"St\u00e9phanie NOUGARET","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/465019f2f3ec45dde981031deb150e5820e952f2838cd6adafd57dcaa95e8c4c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/465019f2f3ec45dde981031deb150e5820e952f2838cd6adafd57dcaa95e8c4c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/465019f2f3ec45dde981031deb150e5820e952f2838cd6adafd57dcaa95e8c4c?s=96&d=mm&r=g","caption":"St\u00e9phanie NOUGARET"}}]}},"_links":{"self":[{"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/posts\/6690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/comments?post=6690"}],"version-history":[{"count":2,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/posts\/6690\/revisions"}],"predecessor-version":[{"id":6706,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/posts\/6690\/revisions\/6706"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/media\/6705"}],"wp:attachment":[{"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/media?parent=6690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/categories?post=6690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ffrdiabete.org\/en\/wp-json\/wp\/v2\/tags?post=6690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}